OncoSec Medical Inc. Announces Formation of Melanoma Advisory Board
SAN DIEGO, Feb. 26, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced the formation of a Melanoma Advisory Board (MAB) for the company's metastatic melanoma program.
(Logo: http://photos.prnewswire.com/prnh/20120905/LA68078LOGO)
Bringing together a group of distinguished industry experts in the melanoma and immunotherapy space, the MAB will provide insight and expertise into OncoSec's clinical strategies for the development of the company's ImmunoPulse program for the treatment of metastatic melanoma.
Punit Dhillon, President and CEO of OncoSec, stated, "We have assembled an impressive group of thought-leaders who have unparalleled experience developing pioneering intralesional therapies. Their expertise will be invaluable in establishing electroporation as a premier delivery mechanism for gene therapies and ImmunoPulse as a first-in-class commercial treatment of aggressive metastatic disease."
Chaired by Dr. Adil I. Daud, the MAB is comprised of five individuals:
Dr. Sanjiv S. Agarwala
Sanjiv K. Agarwala, M.D. is Chief of Medical Oncology & Hematology and Director of the Melanoma and Immunology Program at St. Luke's Cancer Center, Bethlehem, PA. He is Professor of Medicine at Temple University School of Medicine, Philadelphia, PA. He is nationally and internationally recognized as an expert in the research and treatment of melanoma.
Dr. Adil I. Daud
Adil I. Daud, M.D. is a professor of medicine at the University of California San Francisco and a nationally recognized expert in early phase drug development in skin cancer and solid tumors. Prior to joining UCSF Medical Center, he was Associate Professor and Director of the Affiliate Network at the Moffitt Cancer Center in Tampa, FL for seven years. Dr. Daud has won numerous awards, including the American Society for Clinical Oncology's Young Investigator Award.
Dr. Axel Hauschild
Axel Hauschild, M.D., Ph.D. is professor and head of the Interdisciplinary Skin Cancer Center at the Department of Dermatology, University Hospital Schleswig-Holstein in Kiel, Germany. From 2002 to 2010 he was the chairman of the Dermatologic Cooperative Oncology Group (DeCOG) in Germany. Dr. Hauschild is a board member of the European Association of Dermato-Oncology (EADO) and the co-chairman of the Global Melanoma Task Force (GMTF).
Dr. Kim A. Margolin
Kim A. Margolin, M.D. is Professor of Medicine at the University of Washington in Seattle and a member of the Clinical Research Division at the Fred Hutchinson Cancer Research Center. Dr. Margolin served as chair of the Cancer Education Committee for ASCO in 2010 and has previously served on the Board of Directors of the Society for Immunotherapy of Cancer, the Medical Oncology Boards subcommittee of the ABIM (2002-2008), and the Oncologic Drugs Advisory Committee to the FDA (1994-2000).
Dr. Vernon K. Sondak
Vernon K. Sondak, M.D. is Chair of the Department of Cutaneous Oncology and Director of Surgical Education at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, FL. He is also a Professor in the Departments of Oncologic Sciences and Surgery at the University of South Florida Morsani College of Medicine.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives. OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/.
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
SOURCE OncoSec Medical Inc.